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Background
A significant number of HIV Mexican infected people
are in virological failure, many of them are multiply
experienced to antiretroviral therapy.
Objective
To assess the prevalence of resistance mutations in HIV
Mexican infected patients heavily experienced to antire-
troviral therapy (ART).
Materials and methods
A transversal observational study of resistance profiles in
strains from HIV-1 infected patients multiple experienced
to ART was analyzed by a national committee of HIV
drugs resistance in Mexico (GERA-1 IMSS). Mutations
were defined according Stanford Resistance Database.
Results
We assessed 178 subjects, mean age (SD ±) of our subjects
was 41.9 ± 11.9; 91% where male, who failed 2 to 15 ART
regimen (median 5). CDC status was A 20%, B 21% and C
59%; 4% were coinfected with HBV and 2% were infected
with HCV. Month median drug exposure was 121 (range
12-219). Ninety nine (55.6%) had triple class drug muta-
tions, 170 (95.5%) had NRTI mutations, 113 (63.5%) had
NNRTI mutations and 173 (97.2%) had PIs mutations. The
most frequent NRTI mutation belonged to TAM pathways,
74 (41.6%) to TAM1 and 40 (22.5%) to TAM2. These
mutations were 215Y/F 139 (77.7%), M41L 111 (62%),
D67N 97 (54.2%), L210W 85 (47.5%), K219E/Q 60 (33.5%)
and K70R 53 (29.6%) and reflect the extensive use of ZDV
and d4T. K65R was found in 8 (4.4%), Q151M was found
in 2 (1.1%) and insertion 69 in 1 (.5 %). The most frequent
NNRTI mutation was K103N in 57 (31.8%) followed by
Y181C 40 (22.3%), G190A/S 40 (22.3%), V108I 18 (10%),
K101E 16 (8.9%), L100I 13 (7.3%), Y188L 11(6.1%), A98G
10(5.6%), V90I 9 (5%); 14 (8%) of them had resistance to
ETV. Most common PI major mutation were L10V/F 144
(80%), I54L/M/V 126 (70.4%), M36I/L 102 (57%), L90M
101 (56%), 82A/T 92 (51.4%), M46I/L 91 (50.8%), L33F/I
69 (38.5%), I84V 64 (35%) and others. 15 (8.4%) of them
h a dr e s i s t a n c et oD R Va n d3 3( 1 8 . 5 % )t oT P V .
Conclusions
Long term exposure to ART and fluctuating adherence
has led to the selection of multiresistant strains in Mexi-
can HIV infected patients, many of them have resistance
mutation for ART of new generation.
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